Butyrylcholinesterase activity in young men and women: Association with cardiovascular risk factors

Clinical Biochemistry

Volumn 44, Issue 8-9, 2011, Pages 623-626

  Stojanov, Marina ^a   Stefanović, Aleksandra ^a   Džingalašević, Gordana ^b   Mandić Radić, Slavka ^b   Prostran, Milica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Ministry of Internal Affairs   (Serbia)

Author keywords

BMI; Butyrylcholinesterase; Glucose; Lipids; Lipoproteins

Indexed keywords

ALBUMIN; CHOLESTEROL; CHOLINESTERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ALBUMIN BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; BLOOD PRESSURE; BUTYRYLCHOLINESTERASE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; REGRESSION ANALYSIS; RISK FACTORS; YOUNG ADULT;

EID: 79955835076     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.03.028     Document Type: Article

References (30)

1. Kullo I.T., Gau G.T., Tajik A.J. Novel risk factors for atherosclerosis. Mayo Clin Proc 2000, 75:369-380.
2. Ridker P.M., Stampfer M.J., Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc 2001, 285:2481-2485.
3. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-e146.
4. Allender S., Scarborough P., Peto V., Rayner M. European cardiovascular disease statistics 2008 2008, European Heart Network, Brussels, Belgium.
5. Knezevic T. Health statistical yearbook of Republic of Serbia. 2006 2007, 225-272. Institute of public health of Serbia, Belgrade, Serbia.
6. Alcantara V.M., Chautard-Freire-Maia E.A., Scartezini M., Cerci M.S., Braun-Prado K., Picheth G. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest 2002, 62:399-404.
7. Kutty K.M., Payne R.H. Serum pseudocholinesterase and very-low-density lipoprotein metabolism. J Clin Lab Anal 1994, 8:247-250.
8. Rustemeijer C., Schouten J.A., Voerman H.J., Beynen A.C., Donker A.J.M., Heines R.J. Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in type II diabetes mellitus?. Clin Sci 2001, 101:29-35.
9. Crook M., Haq M., Tutt P. Serum lipids, acute phase proteins and serum cholinesterase in normal subjects. Scand J Clin Lab Invest 1994, 54:601-603.
10. Jain R., Kutty M., Huang S.N., Kean K. Pseudocholinesterase/high-density lipoprotein cholesterol ratio in serum of normal persons and of hyperlipoproteinemics. Clin Chem 1983, 29:1031-1033.
11. Cucuianu M., Popescu T.A., Opincaru A., Haragus S. Serum pseudocholinesterase and ceruloplasmin in various types of hyperlipoproteinemia. Clin Chim Acta 1975, 59:19-27.
12. Magarian E.O., Dietz A.J. Correlation of cholinesterase with serum lipids and lipoproteins. J Clin Pharmacol 1987, 27:819-820.
13. Pepys M.B., Rowe I.F., Baltz M.L. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol 1985, 27:83-111.
14. Kalman J., Juhasz A., Rakonczay Z., et al. Increase serum butyrylcholinesterase activity in type IIb hyperlipidemic patients. Life Sci 2004, 75:1195-1204.
15. Randel E.W., Mathews M.S., Zhang H., Seraj J.S., Sun G. Relationship between serum butyrylcholinesterase and metabolic syndrome. Clin Biochem 2005, 78:799-805.
16. Calderon-Margalit R., Adler B., Abramson J.H., Gofin J., Kark J.D. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem 2006, 52:845-852.
17. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
18. Johansen A., Nielsen E.M., Andersen G., et al. Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to type 2 diabetes and insulin secretion. Diabetologia 2004, 47:1437-1441.
19. Valle A., O'Conner D.T., Taylor P., et al. Butyrylcholinesterase: association with the Metabolic syndrome and identification of 2 gene loci affecting activity. Clin Chem 2006, 52:1014-1020.
20. Kuk J.L., Ardern C.I. Age and sex differences in the clustering of metabolic syndrome factors. Diabetes Care 2010, 33:2457-2461.
21. Stojanov M.D., Jovicic D.M., Djuric S.P., Konjevic M.M., Todorovic Z.M., Prostran M.S. Butyrylcholinesterase activity and mortality risk in hemodialysis patients: comparison to hsCRP and albumin. Clin Biochem 2009, 42:22-26.
22. Flegar-Mestric Z., Surina B., Siftar Z. Biological variations of human serum butyrylcholinesterase activity in a population from Zagreb, Croatia. Chem Biol Interact 1999, 119-120:193-199.
23. Van Lith H.A., Beynen A.C. Dietary cholesterol lowers the activity of butyrylcholinesterase (EC 3.1.1.8), but elevates that of esterase-1 (EC 3.1.1.1) in plasma of rats. Br J Nutr 1993, 70:721-726.
24. Finer Y., Jaffer F., Santerre J.P. Mutual influence of cholesterol esterase and pseudocholinesterase on the biodegeneration of dental composites. Biomaterials 2004, 25:1787-1793.
25. Iwasaki T., Yoneda M., Nakajima A., Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med 2007, 46:1633-1639.
26. De Vriese C., Gregorie F., Lema-Kisoka R., Waelbroeck M., Robberecht P., Delponte C. Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. Endocrinology 2004, 145:4997-5005.
27. Srihdar G.R., Rao A.A., Srinvas K., et al. Butyrylcholinesterase in metabolic syndrome. Med Hypothesis 2010, 75:648-651.
28. Mendelson M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801-1811.
29. Moolman J.A. Unravelling the cardioprotective mechanism of action of estrogens. Cardiovasc Res 2006, 69:777-780.
30. Cwiertnia M.M., Alcantara V.M., Rea R.R., et al. Butyrylcholinesterase and diabetes mellitus in CHE2 C5- and CHE2 C5+ phenotypes. Arq Bras Endocrinol Metab 2010, 54:60-67.